

DOR BIOPHARMA INC
Form 4
February 13, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
MYRIANTHOPOULOS EVAN

(Last) (First) (Middle)

1101 BRICKELL AVENUE, SUITE 701-S

(Street)

MIAMI, FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DOR BIOPHARMA INC [DOR]

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock ⁽¹⁾	02/09/2007	02/09/2007	P	Code V Amount (D) Price 53,191 A \$ 0.47	154,817 ⁽²⁾	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: DOR BIOPHARMA INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. I. De. Sec. (In	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	\$ 0.47					11/10/2004	11/10/2014	Common Stock	150,000
Stock Options (right to buy)	\$ 0.58					09/09/2004	09/09/2014	Common stock	50,000
Stock Options (right to buy)	\$ 0.9					09/15/2003	09/15/2013	Common Stock	50,000
Stock Warrants (right to buy)	\$ 0.8756					09/15/2003	09/15/2008	Common Stock	120,888
Stock Warrants (right to buy)	\$ 0.35					12/30/2002	12/30/2007	Common Stock	43,929
Stock Warrants (right to buy)	\$ 0.75					12/30/2002	12/30/2007	Common Stock	21,525
Stock Options (right to buy)	\$ 0.35					11/14/2002	11/14/2012	Common Stock	150,000
Stock Options (right to buy)	\$ 0.49					12/13/2004	12/13/2014	Common Stock	500,000
Stock Warrants	\$ 0.246 <u>(2)</u>					04/10/2006	04/10/2016	Common Stock	90,220

(right to buy)

Stock

Options (right to buy)

\$ 0.35

05/10/2006 05/10/2016

Common Stock 400,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MYRIANTHOPOULOS EVAN 1101 BRICKELL AVENUE SUITE 701-S MIAMI, FL 33131	X		Chief Financial Officer	

Signatures

/s/ Evan

Myrianthopoulos

02/09/2007

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Private purchase of common stock as part of February 2007 PIPE.
- (2) Exercise price changed from 0.45 to 0.246 due to dilutive event occurring on shares issued in Sigma Tau financing also, 11,369 additional shares were issued

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.